What is the NuvaRing?
The NuvaRing is a 2-inch flexible ring that contains both estrogen and progestin (etonogestrel). Eetonogestrel is the active metabolite of the prodrug desogestrel making the NuvaRing a third-generation contraceptive. It is inserted into the vagina. Women can insert the ring by themselves once a month and take it out at the end of the third week to allow menstruation.
The Dangers Associated with Third Generation Contraceptives
In The New York Times Health Guide, they have stated the following:
“All combination estrogen/progestin birth control products carry an increased risk for blood clots in the veins (venous thromboembolism), which can lead to blood clots in the arteries of the leg or lung (pulmonary embolism). The risk is lower for oral contraceptives than for the birth control patch (Ortho Evra) or the ring (NuvaRing), which expose women to higher levels of estrogen than birth control pills.” In addition, the authors of the Health Guide state, “As with the patch (Ortho Evra), NuvaRing may put women who take it at higher risk for blood clots than oral contraceptives.”
Public Citizen has petitioned the FDA on behalf of 100,000 consumers to ban third generation oral contraceptives containing esogestrel (the combination of estrogen and progestin such as in the NuvaRing) due to the approximately doubled risk of venous thrombosis and lack of evidence of clinical benefit as compared to the second generation oral contraceptives.
Types of Claims we are Evaluating
If you or somebody you know has used the NuvaRing and since suffered from any of the following health problems, you should contact us immediately.
- Blood Clots
- Deep Vein Thrombosis, Venous Thrombosis, Venous Thromboembolism
- Pulmonary Embolism
- Pseudotumor Cerebri (PTC)
- Idiopathic Intracranial Hypertension (IIH)
- Benign Intracranial Hypertension (BIH)
- Heart Attack, Myocardial Infarction (MI or AMI for Acute Myocardial Infarction)
- Stroke, Cerebrovascular Accident